Table 2 Biomarkers associated with PFS and OS in the lenvatinib-plus-everolimus arm, as determined by HR.

From: Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

Marker

Cut-off

Low group

High group

Log-rank P value

Direction of HR: high/low

Quantile

Value

n

MST

n

MST

 

With FDR

HR (95% CI)

Association with PFS

 ANG-2

0.5

6.800 μg/L

27

20.1

21

5.9

0.0351

0.1508

2.360 (1.040–5.355)

 HGF

0.5

7.350 μg/L

28

20.1

20

5.6

0.0264

0.1508

2.550 (1.088–5.974)

 IL-18

0.5

264.0 ng/L

28

14.7

20

5.6

0.0317

0.1508

2.418 (1.058–5.526)

 IL-18BP

0.5

17.0 μg/L

24

17.5

24

6.9

0.0305

0.1508

2.431 (1.059–5.580)

 M-CSF

0.5

0.9650 μg/L

28

14.7

20

7.4

0.1144

0.3088

1.904 (0.845–4.288)

 MIG

0.5

1250 ng/L

30

20.1

18

7.4

0.0299

0.1508

2.506 (1.062–5.914)

 TIMP-1

0.5

199.0 μg/L

26

14.7

22

5.6

0.0392

0.1508

2.326 (1.023–5.291)

 VEGF

0.5

305.0 ng/L

29

14.7

19

11.2

0.2526

0.5247

1.597 (0.711–3.587)

Association with OS

 ANG-2

0.5

6.800 μg/L

27

NE

21

21.7

0.003

0.0137

3.005 (1.402–6.442)

 HGF

0.5

7.350 μg/L

28

32.2

20

20.5

0.0081

0.0258

2.592 (1.249–5.377)

 IL-18

0.5

264.0 ng/L

28

32.1

20

20.7

0.0163

0.0367

2.376 (1.149–4.915)

 IL-18BP

0.5

17.00 μg/L

24

32.2

24

18.4

0.0008

0.0073

3.469 (1.605–7.501)

 M-CSF

0.5

0.9650 μg/L

28

NE

20

14.5

0.0002

0.0044

3.765 (1.781–7.959)

 MIG

0.5

1250 ng/L

30

25.5

18

25.5

0.9668

0.9668

0.985 (0.472–2.056)

 TIMP-1

0.5

199.0 μg/L

26

NE

22

16.1

0.0003

0.0044

3.770 (1.741–8.162)

 VEGF

0.5

305.0 ng/L

29

32.2

19

20.5

0.0021

0.0137

2.993 (1.441–6.213)

  1. Biomarkers most strongly associated with PFS or OS (by HR), respectively, are shaded grey.
  2. ANG-2 angiopoietin-2, FDR false discovery rate, HGF hepatocyte growth factor, HR hazard ratio, IL-18 interleukin-18, IL-18BP interleukin-18 binding protein, M-CSF macrophage colony-stimulating factor, MIG monokine induced by gamma interferon, MST median survival time, NE not estimable, OS overall survival, PFS progression-free survival, TIMP-1 tissue inhibitor of metalloproteinase-1, VEGF vascular endothelial growth factor.
Back to article page